JP2005536455A5 - - Google Patents

Download PDF

Info

Publication number
JP2005536455A5
JP2005536455A5 JP2003583337A JP2003583337A JP2005536455A5 JP 2005536455 A5 JP2005536455 A5 JP 2005536455A5 JP 2003583337 A JP2003583337 A JP 2003583337A JP 2003583337 A JP2003583337 A JP 2003583337A JP 2005536455 A5 JP2005536455 A5 JP 2005536455A5
Authority
JP
Japan
Prior art keywords
tweak
use according
antibody
cells
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003583337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005536455A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/011350 external-priority patent/WO2003086311A2/en
Publication of JP2005536455A publication Critical patent/JP2005536455A/ja
Publication of JP2005536455A5 publication Critical patent/JP2005536455A5/ja
Pending legal-status Critical Current

Links

JP2003583337A 2002-04-09 2003-04-09 Ｔｗｅａｋ関連状態を治療するための方法 Pending JP2005536455A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37161102P 2002-04-09 2002-04-09
PCT/US2003/011350 WO2003086311A2 (en) 2002-04-09 2003-04-09 Methods for treating tweak-related conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009202035A Division JP5603040B2 (ja) 2002-04-09 2009-09-01 Ｔｗｅａｋ関連状態を治療するための方法

Publications (2)

Publication Number Publication Date
JP2005536455A JP2005536455A (ja) 2005-12-02
JP2005536455A5 true JP2005536455A5 (https=) 2006-01-26

Family

ID=29250708

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003583337A Pending JP2005536455A (ja) 2002-04-09 2003-04-09 Ｔｗｅａｋ関連状態を治療するための方法
JP2009202035A Expired - Fee Related JP5603040B2 (ja) 2002-04-09 2009-09-01 Ｔｗｅａｋ関連状態を治療するための方法
JP2011196571A Withdrawn JP2012021014A (ja) 2002-04-09 2011-09-08 Ｔｗｅａｋ関連状態を治療するための方法
JP2014016608A Expired - Fee Related JP5916776B2 (ja) 2002-04-09 2014-01-31 Ｔｗｅａｋ関連状態を治療するための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009202035A Expired - Fee Related JP5603040B2 (ja) 2002-04-09 2009-09-01 Ｔｗｅａｋ関連状態を治療するための方法
JP2011196571A Withdrawn JP2012021014A (ja) 2002-04-09 2011-09-08 Ｔｗｅａｋ関連状態を治療するための方法
JP2014016608A Expired - Fee Related JP5916776B2 (ja) 2002-04-09 2014-01-31 Ｔｗｅａｋ関連状態を治療するための方法

Country Status (19)

Country Link
US (5) US20060240004A1 (https=)
EP (4) EP1494713A4 (https=)
JP (4) JP2005536455A (https=)
KR (2) KR101000842B1 (https=)
CN (5) CN1658901A (https=)
AU (1) AU2003224950B2 (https=)
BR (1) BRPI0309126A8 (https=)
CA (2) CA2887716C (https=)
DK (1) DK1997512T3 (https=)
EA (1) EA011607B1 (https=)
ES (1) ES2444121T3 (https=)
IL (3) IL164352A0 (https=)
MX (2) MX352180B (https=)
NO (2) NO334266B1 (https=)
NZ (2) NZ536348A (https=)
PT (1) PT1997512E (https=)
SI (1) SI1997512T1 (https=)
WO (1) WO2003086311A2 (https=)
ZA (1) ZA200408073B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
AU5951901A (en) 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
MX352180B (es) 2002-04-09 2017-11-13 Biogen Ma Inc El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
WO2005053728A2 (de) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
AU2011239311B2 (en) * 2005-02-17 2014-05-22 Biogen Ma Inc. Treating Neurological Disorders
US20090068102A1 (en) * 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
WO2006089095A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
EP1764109A1 (de) * 2005-05-24 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den Tweak Rezeptor Fn14 binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
MEP35408A (en) 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
CA2729351C (en) 2008-06-30 2017-01-24 University Of Pennsylvania Fn14/trail fusion proteins
WO2010019234A1 (en) * 2008-08-12 2010-02-18 Ihc Intellectual Asset Management, Llc Analysis of genetic markers for peripartum cardiomyopathy
JP5161718B2 (ja) * 2008-09-25 2013-03-13 株式会社ゲノム創薬研究所 肝障害モデル動物、及びそれを用いた肝障害を改善又は予防する、薬剤若しくは食品素材のスクリーニング方法
MX2011007936A (es) * 2009-01-30 2011-08-17 Biogen Idec Inc Metodos para regeneracion de tejido pancreatico.
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9096879B2 (en) * 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
US9068004B2 (en) 2010-02-04 2015-06-30 University Of Louisville Research Foundation, Inc. TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
AU2011311673B2 (en) 2010-10-05 2015-09-17 F. Hoffmann-La Roche Ag Antibodies against human TWEAK and uses thereof
RU2462222C1 (ru) * 2011-07-11 2012-09-27 Наталья Николаевна Молчанова Способ лечения больных артериальной гипертонией с метаболическими нарушениями
HK1198832A1 (en) * 2011-08-23 2015-06-12 Transbio Ltd Fn14 binding proteins and uses thereof
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
CA2958585C (en) * 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
AU2015336946A1 (en) * 2014-10-23 2017-04-13 La Trobe University Fn14-binding proteins and uses thereof
KR101881531B1 (ko) * 2016-11-25 2018-07-25 고려대학교 산학협력단 폴리-2-하이드록시에틸 메타아크릴레이트를 이용한 사이토카인의 발현능이 증가된 줄기세포의 제조방법
AU2021331368A1 (en) * 2020-08-28 2023-03-16 Resolution Therapeutics Limited Modified immune cells for fibrosis and inflammation
CN113616777A (zh) * 2021-08-18 2021-11-09 中山大学附属第三医院（中山大学肝脏病医院） 基于主要尿蛋白改善内质网应激的转化应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5200313A (en) 1983-08-05 1993-04-06 Miles Inc. Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
US4921698A (en) 1984-05-25 1990-05-01 Asahi Kasei Kogyo Kabushiki Kaisha Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AT396939B (de) 1990-05-29 1993-12-27 Alois Dipl Ing Dr Jungbauer Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US6544761B2 (en) 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
ES2281898T3 (es) 1994-12-13 2007-10-01 Human Genome Sciences, Inc. Inhibidor tisular humano de metaloproteinasa-4.
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
CZ297387B6 (cs) 1996-08-07 2006-11-15 Biogen Idec Ma Inc. Sekvence DNA kódující ligand príbuzný TNF, polypeptid a zpusob jeho prípravy, protilátka reaktivní s polypeptidem a farmaceutická kompozice
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US5858991A (en) 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
CA2280231A1 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU7549498A (en) 1997-06-03 1998-12-21 Protegene Inc. Human proteins having transmembrane domains and dnas encoding these prot eins
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
JP4303883B2 (ja) 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体
EP1021542B1 (en) 1997-10-10 2009-03-04 Genentech, Inc. Apo-3 ligand
US20020072089A1 (en) 1999-11-23 2002-06-13 Holtzman Douglas A. Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
WO1999059614A1 (en) 1998-05-20 1999-11-25 Yale University Modulation of angiogenesis and wound healing
EP1080194A2 (en) 1998-05-29 2001-03-07 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
CA2345382A1 (en) 1998-10-16 2000-04-27 Immunex Corporation Inhibitors of platelet activation and recruitment
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
ES2327785T3 (es) 1998-12-22 2009-11-03 Genentech, Inc. Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas.
MXPA01007163A (es) 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
PT1626058E (pt) 1999-03-08 2008-02-15 Genentech Inc Composições e métodos para o diagnóstico de tumores
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
KR100510795B1 (en) 1999-08-31 2005-08-30 Compositions and Methods for the Treatment of Tumor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
EP2298333A3 (en) * 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
IL150571A0 (en) 2000-01-03 2003-02-12 Tr Associates L L C Novel chimeric proteins and methods for using the same
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
NZ521437A (en) 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
AU5951901A (en) 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US20040047854A1 (en) 2001-07-27 2004-03-11 Black Roy A. Human disintegrin protein
AU8901901A (en) * 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
JP4344519B2 (ja) 2000-12-28 2009-10-14 旭化成ファーマ株式会社 ＮＦ−κＢ活性化遺伝子
EP1379264A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences Inc HUMAN SECRETED PROTEINS
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2003040307A2 (en) 2001-07-27 2003-05-15 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
US20040091473A1 (en) 2001-07-27 2004-05-13 Dubose Robert F. Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
US20030148314A1 (en) 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US7087225B2 (en) 2001-08-16 2006-08-08 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
MX352180B (es) 2002-04-09 2017-11-13 Biogen Ma Inc El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
WO2004079014A2 (en) 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
DE602004006871T2 (de) 2003-07-24 2008-02-07 Amgen Inc., Thousand Oaks Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen
EP1566636A1 (en) 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
EP1811838A4 (en) 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
US20090068102A1 (en) 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
EP1853312B1 (en) 2005-03-07 2014-12-10 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
MEP35408A (en) 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20100284933A1 (en) 2006-10-16 2010-11-11 Biogen Idec Ma Inc. Biomarkers of Multiple Sclerosis
MX2010012324A (es) 2008-05-15 2011-01-14 Biogen Idec Inc Anticuerpos anti-fn14 y usos de los mismos.
WO2010085648A2 (en) 2009-01-23 2010-07-29 Linda Burkly C Methods for reducing radiation-induced tissue damage
MX2011007936A (es) 2009-01-30 2011-08-17 Biogen Idec Inc Metodos para regeneracion de tejido pancreatico.
AU2011311673B2 (en) 2010-10-05 2015-09-17 F. Hoffmann-La Roche Ag Antibodies against human TWEAK and uses thereof

Similar Documents

Publication Publication Date Title
JP2005536455A5 (https=)
Brittan et al. Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon
De Coppi et al. Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells
Russo et al. The bone marrow functionally contributes to liver fibrosis
Kitamura et al. Establishment and characterization of renal progenitor like cells from S3 segment of nephron in rat adult kidney
Strutz et al. Renal fibroblasts and myofibroblasts in chronic kidney disease
Fiore et al. Pharmacological blockage of fibro/adipogenic progenitor expansion and suppression of regenerative fibrogenesis is associated with impaired skeletal muscle regeneration
Meier et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice
JP5450072B2 (ja) 組織修復および再生における腎臓由来細胞およびその使用方法
Yannaki et al. G-CSF–primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs
Li et al. Low levels of TGF-β1 enhance human umbilical cord-derived mesenchymal stem cell fibronectin production and extend survival time in a rat model of lipopolysaccharide-induced acute lung injury
Reinecke et al. Transmural replacement of myocardium after skeletal myoblast grafting into the heart: too much of a good thing?
Li et al. Targeted migration of bone marrow mesenchymal stem cells inhibits silica-induced pulmonary fibrosis in rats
Plotkin et al. Mesenchymal cells from adult kidney support angiogenesis and differentiate into multiple interstitial cell types including erythropoietin-producing fibroblasts
Li et al. Bone marrow cell infusion ameliorates progressive glomerulosclerosis in an experimental rat model
JP7405345B2 (ja) 間葉系幹細胞の動員活性を有するペプチド
CA2254954A1 (en) Morphogen treatment for chronic renal failure
Gong et al. Differentiation of rat mesenchymal stem cells transplanted into the subretinal space of sodium iodate‐injected rats
Ding et al. Essential role of stem cell factor–c‐Kit signalling pathway in bleomycin‐induced pulmonary fibrosis
CN104105493A (zh) 哺乳动物胎儿肺细胞以及其治疗用途
Ricardo et al. Adult stem cells in renal injury and repair
US20200289582A1 (en) Conditioning protocols and use of same for tissue regeneration
Roxburgh et al. Recapitulation of embryological programmes in renal fibrosis–the importance of epithelial cell plasticity and developmental genes
Li et al. Renal and bone marrow cells fuse after renal ischemic injury
Sharma et al. Growth factor and small molecule influence on urological tissue regeneration utilizing cell seeded scaffolds